Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946

National Institute for Health and Care Excellence (NICE)
Record ID 32018012031
Project Status: Completed
Year Published: 2024
URL for published report: https://www.nice.org.uk/guidance/ta946
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England
MeSH Terms
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Bevacizumab
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Ovarian Epithelial
  • Poly(ADP-ribose) Polymerase Inhibitors
Organisation Name: National Institute for Health and Care Excellence
Contact Address: Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.